Chimeric receives $1.8 M advance on FY26 R&D tax incentive
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The funds will be utilized to support the clinical trial pipeline and for general working capital purposes. The funding agreement allows Chimeric to access a portion of its expected tax incentive early, with repayment scheduled to follow the anticipated receipt of the incentive. Chimeric is focused on developing innovative cell therapies for cancer treatment and currently has multiple clinical stage programs underway.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Half Year Report and Appendix 4D 31 December 2025
- Portfolio streamlined - return of CHM CLTX to City of Hope
- Funding and EGM update
- Quarterly Activities/Appendix 4C Cash Flow Report
- $8.4 M funding to drive CHM CDH17 and resignation of CMO
Later from Chimeric Therapeutics
- Consolidation/Split - CHM
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- CHM announces positive Phase 1/2 data at ASCO
- Appointment of Financial Adviser for Strategic Review
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics